Indian API maker slammed by US FDA for water and cleaning issues

By Dan Stanton

- Last updated on GMT

Image: iStock/Singh_Lens
Image: iStock/Singh_Lens

Related tags Pharmaceutical drug Fda

The US FDA has issued a warning letter to Indian API maker Resonance Laboratories Private Limited citing inadequate cleaning procedures at its facility in Bangalore.

The warning letter​ was sent by the US Food and Drug Administration (FDA) earlier this month following an inspection at the Doddaballapur, Bangalore in May last year.

According to the Agency, Resonance Laboratories failed to validate its water system and failed to have adequate cleaning procedures to prevent contamination of its active pharmaceutical ingredients (APIs).

“You failed to demonstrate that distilled water used to clean equipment downstream of the (b)(4) purification steps is suitable for use,” ​the Agency said. “For example, the distilled water used for cleaning equipment in the (b)(4) cleanrooms, after passing through a (b)(4) micrometer filter, had an unacceptable level of bioburden.”

The Agency noted that while the firm used shared equipment across a number of APIs, data from cleaning verification and validation studies found the cleaning procedures were ineffective.

“For example, our investigator discovered that 105 of (b)(4) cleaning verification samples taken between 2015 and the start of our 2016 inspection failed your firm’s specification of no more than (b)(4) ppm for residual drug,”​ the letter said.

“After obtaining failing cleaning verification results, you repeated cleaning until you obtained passing verification results. Your firm failed to investigate recurring cleaning procedure ineffectiveness and did not remediate the deficient procedures.”

According to Resonance Laboratories’ website​, six US Drug Master Files (DMF) cite APIs made by the firm: Atropine Sulfate, Buprenorphine Hydrochloride, Clidinium Bromide, Glycopyronium Bromide, Homatropine Methylbromide, and Oxybutynin Chloride/Oxybutynin Hydrochloride.

Based upon the FDA’s findings, the Agency has recommended the firm engages an independent consultant to assist in meeting cGMP requirements.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more